Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 1.00 |
| ▸ | CETP | P11597 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 3/20 | 0.61 |
| ▸ | GMNN | O75496 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.61 |
| ▸ | CCR6 | P51684 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | UBE2N | P61088 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylspingosine SCHEMBL5493697 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1CETPMEN1KMT2A | |
| Dimethylspingosine SCHEMBL8258015 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1CETPMEN1KMT2A | |
| Dimethylspingosine SCHEMBL121926 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1CETPMEN1KMT2A | |
| Dimethylspingosine SCHEMBL19745875 | 0.93 | SPHK2 (0.86) | SPHK2SPHK1CETPMEN1KMT2A | |
| SCHEMBL14020662 | 0.85 | SPHK2 (0.74) | SPHK2SPHK1CETPMEN1KMT2A | |
| SCHEMBL8912325 | 0.85 | SPHK2 (0.74) | SPHK2SPHK1CETPMEN1KMT2A | |
| SCHEMBL21428462 | 0.84 | SPHK2 (0.72) | SPHK2SPHK1CETPMEN1KMT2A | |
| SCHEMBL29455695 | 0.83 | SPHK2 (0.70) | SPHK2SPHK1CETPMEN1KMT2A | |
| SCHEMBL11895494 | 0.79 | SPHK2 (0.69) | SPHK2SPHK1CETPMEN1KMT2A | |
| Sphingosine SCHEMBL27529594 | 0.79 | SPHK2 (0.90) | SPHK2SPHK1CETPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| US-11252974-B2 | Oxidation inhibitor, and food and drink containing fats and oils using same | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-02-22 | — | — | US | claimed |
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS (FORTH) (GR) | 2021-08-12 | — | — | US | claimed |
| EP-3841097-A1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | Biomedical Research Foundation of the Academy of Athens (GR) | 2021-06-30 | — | — | EP | claimed |
| WO-2020039097-A1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (BRFAA) (GR) | 2020-02-27 | — | — | WO | claimed |
| US-20190175725-A1 | Prophylactic and Immunomodulatory Compositions and Uses | KHERION BIOTECH INC. | 2019-06-13 | — | — | US | claimed |
| US-10287294-B2 | Compounds for use in treating or preventing cancerous diseases | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2019-05-14 | — | — | US | claimed |
| US-20180208597-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2018-07-26 | — | — | US | claimed |
| EP-3319965-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | Biomedical Research Foundation of the Academy of Athens (GR) | 2018-05-16 | — | — | EP | claimed |
| WO-1998033528-A9 | INDUCTION OF B CELL TOLERANCE | BIOTRANSPLANT INC (US) | 2001-06-14 | — | — | WO | claimed |
| EP-0969872-A2 | INDUCTION OF B CELL TOLERANCE | BIOTRANSPLANT, INC (US) | 2000-01-12 | — | — | EP | claimed |
| WO-1998033528-A2 | INDUCTION OF B CELL TOLERANCE | BIOTRANSPLANT, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0565587-B1 | THE EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON PROTEIN KINASE-C ACTIVITY; MELANOMA CELL GROWTH $i(IN VITRO); METASTATIC POTENTIAL $i(IN VIVO) AND HUMAN PLATELET AGGREGATION | ONCOMEMBRANE INC (US) | 1997-03-12 | — | — | EP | claimed |
| EP-0381514-B1 | Use of N-methyl-sphingosine as inhibitor of cell growth | BIOMEMBRANE INST (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0565587-A4 | THE EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON PROTEIN KINASE-C ACTIVITY; MELANOMA CELL GROWTH -I(IN VITRO); METASTATIC POTENTIAL -I(IN VIVO) AND HUMAN PLATELET AGGREGATION | BIOMEMBRANE INST (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0565587-A1 | THE EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON PROTEIN KINASE-C ACTIVITY; MELANOMA CELL GROWTH -i(IN VITRO); METASTATIC POTENTIAL -i(IN VIVO) AND HUMAN PLATELET AGGREGATION. | BIOMEMBRANE INST (US) | 1993-10-20 | — | — | EP | claimed |
| US-5248824-A | Method of preparing N,N,N-trimethylsphingosine | THE BIOMEMBRANE INSTITUTE (US) | 1993-09-28 | — | — | US | claimed |
| US-5151360-A | EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON PROTEIN KINASE-C ACTIVITY, MELANOMA CELL GROWTH IN VITRO, METASTATIC POTENTIAL IN VIVO AND HUMAN PLATELET AGGREGATION | BIOMEMBRANE INSTITUTE (US) | 1992-09-29 | — | — | US | claimed |
| WO-1992012119-A1 | THE EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON PROTEIN KINASE-C ACTIVITY; MELANOMA CELL GROWTH IN VITRO; METASTATIC POTENTIAL IN VIVO AND HUMAN PLATELET AGGREGATION | THE BIOMEMBRANE INSTITUTE (US) | 1992-07-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | PIK3R3, PIK3CA, PIK3C2A | SPHK2 1585/4885SPHK1 1863/4885CETP 4227/4885 |
| US-20180208597-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BRCA1, VHL, TSG101 | SPHK2 805/4885SPHK1 866/4885CETP 345/4885 |
| US-10287294-B2 | Compounds for use in treating or preventing cancerous diseases | BRCA1, VHL, CYP27A1 | SPHK2 1277/4885SPHK1 1290/4885CETP 364/4885 |
| US-20190175725-A1 | Prophylactic and Immunomodulatory Compositions and Uses | SPHK1, S1PR1, SPHK2 | SPHK2 3/4885SPHK1 1/4885CETP 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.